Cardiovascular Diseases Clinical Trial
Official title:
Emotion Regulation Training to Reduce Cardiovascular Disease Risk Among Depressed Young Adults in Southern Mississippi: A Single-Session Design
Verified date | May 2024 |
Source | University of Southern Mississippi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The proposed study will investigate the utility of a single-session emotion regulation training to reduce CVD risk among young adults diagnosed with MDD living in Southern MS. Using an single-arm, non-randomized design, young adults aged 18-29 will undergo a single-session emotion regulation skills training. Before and immediately after the skills training session, participants will supply several biological metrics tied to CVD risk: resting HRV, inflammation (measured via c-reactive protein [CRP]), and blood pressure. Participants will provide the same biological metrics at a one-week follow-up visit to assess short-term sustained gains following the single-session intervention and complete a 7-day ecological momentary assessment (EMA) of their daily emotion regulation skills use and depressive symptoms between these two visits.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 29 Years |
Eligibility | Inclusion Criteria: 1. Men and women ages 18-29 2. Able to speak and read English 3. Outpatient at the time of participation 4. Able to provide informed consent 5. Stable medications for 30 days or more 6. Appropriate diagnoses: - Meets diagnostic criteria for current major depressive disorder Exclusion Criteria: 1. Not fluent in English 2. Not able to provide informed consent 3. Active suicidal ideation 4. Presence of autoimmune and/or inflammatory diseases (e.g., rheumatoid arthritis, ulcerative colitis) 5. Ongoing use of steroids (if use of steroids is temporary, individuals are eligible to participate 30 days after termination) 6. Medication change in the past 30 days (individuals are eligible to participate 30 days after a medication change and may take advantage of delayed scheduling) 7. Meets diagnostic criteria for a schizophrenia-spectrum disorder, substance use disorder, and/or bipolar disorder 8. Presence of a cardiovascular disease (e.g., hypertension) or prescribed cardiovascular medications (e.g., beta blockers, blood pressure medication) |
Country | Name | City | State |
---|---|---|---|
United States | University of Southern Mississippi | Hattiesburg | Mississippi |
Lead Sponsor | Collaborator |
---|---|
University of Southern Mississippi |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Diastolic Blood Pressure | Diastolic blood pressure will be measured prior to the training, immediately afterwards, and during the 1-week follow-up visit | Change from prior to the single-session emotion regulation training to immediately after and 1-week after | |
Primary | Change in Systolic Blood Pressure | Systolic blood pressure will be measured prior to the training, immediately afterwards, and during the 1-week follow-up visit | Change from prior to the single-session emotion regulation training to immediately after and 1-week after | |
Primary | Change in Resting Heart Rate Variability (HRV) | Resting heart rate variability (HRV) will be measured prior to the training, immediately afterwards, and during the 1-week follow-up visit | Change from prior to the single-session emotion regulation training to immediately after and 1-week after | |
Primary | Change in C-reactive protein (CRP) | C-reactive protein (CRP) will be measured prior to the training, immediately afterwards, and during the 1-week follow-up visit | Change from prior to the single-session emotion regulation training to immediately after and 1-week after | |
Primary | Change in Center for Epidemiological Studies - Depression Scale (CESD) | Depressive symptoms will be assessed using the CESD prior to the training, immediately afterwards, and at the 1-week follow-up visit. Depressive symptoms will also be assessed during the EMA assessment period. | Change from prior to the single-session emotion regulation training to immediately after and 1-week after | |
Secondary | Change in Emotion Regulation Questionnaire, Reappraisal subscale (ERQ-R) | Reappraisal Skills will be measured by the ERQ-R and assessed prior to the training, immediately afterwards, and at the 1-week follow-up visit. Reappraisal skills will also be assessed during the EMA assessment period. | Change from prior to the single-session emotion regulation training to immediately after and 1-week after | |
Secondary | Change in Experiences Questionnaire - Decentering (EQ-D) | Decentering skills, measured by the EQ-D, will be assessed prior to the training, immediately afterwards, and at the 1-week follow-up visit. Decentering skills will also be assessed during the EMA assessment period. | Change from prior to the single-session emotion regulation training to immediately after and 1-week after | |
Secondary | Change in Difficulties with Emotion Regulation Scale (DERS) | Emotion Dysregulation, measured by the DERS, will be assessed prior to the training, immediately after, and at the 1-week follow-up visit. | Change from prior to the single-session emotion regulation training to immediately after and 1-week after |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|